srpt gene therapy - Search News

News

Sarepta, gene therapy

Exclusive: US FDA to ask Sarepta to stop shipments of gene therapy Elevidys, source says

The U.S. Food and Drug Administration is planning to ask Sarepta Therapeutics to voluntarily stop all shipments of its gene therapy Elevidys, a source familiar with the matter told Reuters on Friday.

GEN - Genetic Engineering and Biotechnology News · 1d

StockWatch: Sarepta Shares Nosedive after LGMD Gene Therapy Patient Dies

· 2d

Sarepta's Setback Deepens With Another Gene Therapy Fatality

50mon MSN

Sarepta extends losses premarket after refusing FDA’s halt request

Sarepta Therapeutics (SRPT) shares fell as much as 4.8% in premarket trading Monday, poised to extend losses for a second ...

Sarepta Therapeutics: What's Happening With SRPT Stock?

The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

Insider Monkey6mon

Sarepta Therapeutics, Inc. (SRPT): Is This Gene Therapy Stock a Good ...

The cornerstone of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)’s recent success has been ELEVIDYS, a gene therapy approved by the FDA in June 2023, and later expanded in 2024 to treat ambulatory ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results